CPT code 91320 identifies a SARS–CoV–2 vaccine product (tris–sucrose formulation) supplied as a 30 mcg/0.3 mL dose for intramuscular injection to reduce the risk of COVID–19. Nationally, COVID–19 vaccination codes remain central to public health immunization efforts, coverage policies, and payer reimbursement frameworks. This code informs billing for vaccine acquisition distinct from administration fees and is used across outpatient and community vaccination settings.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what 91320 represents clinically and operationally, typical places where the vaccine is administered, and which major payers commonly cover such vaccine products. The publication also summarizes common modifiers and the practical contexts in which the code is billed. Where specific data elements were not provided, the report notes the absence of that input.

This summary is intended for billing managers, revenue-cycle professionals, and policy analysts who need a clear, national-level description of CPT code 91320, its clinical purpose, and the payer landscape relevant to COVID–19 vaccine product billing.